Blood Res.  2017 Jun;52(2):137-139. 10.5045/br.2017.52.2.137.

Acute megakaryoblastic blast crisis as a presentation manifestation of chronic myelogenous leukemia

• Bhattacharya JB
• Gupta R
• Samadhiya

• KMID: 2413333
• DOI: http://doi.org/10.5045/br.2017.52.2.137

Abstract

No abstract available.

MeSH Terms

Blast Crisis*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
Megakaryocyte Progenitor Cells*

Figure

• 

  Fig. 1 (A) PCR showing bcr-abl positivity and (B) T315I mutation (L, 100 bp ladder; P1, Positive Control; P2, positive for (A) BCR/ABL or (B) T315).

• 

  Fig. 2 (A) Bone marrow aspiration showing blasts with abundant granular cytoplasm and small vesicular nuclei (Giemsa, ×400). (B) Bone marrow biopsy showed replacement of hematopoietic precursors with blasts with vesicular nuclei and prominent nucleoli (H & E, ×400). (C) Biopsy showed blasts positive for CD61 and (D) positive for CD34.

Reference

1. Choi W, Kim M, Lim J, et al. Four cases of chronic myelogenous leukemia in mixed phenotype blast phase at initial presentation mimicking mixed phenotype acute leukemia with t(9;22). Ann Lab Med. 2014; 34:60–63.

2. Pagano L, Pulsoni A, Vignetti M, et al. Acute megakaryoblastic leukemia: experience of GIMEMA trials. Leukemia. 2002; 16:1622–1626.

3. Al-Shehri A, Al-Seraihy A, Owaidah TM, Belgaumi AF. Megakaryocytic blast crisis at presentation in a pediatric patient with chronic myeloid leukemia. Hematol Oncol Stem Cell Ther. 2010; 3:42–46.

4. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004; 103:4010–4022.

5. Luatti S, Castagnetti F, Marzocchi G, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood. 2012; 120:761–767.

6. Fruehauf S, Topaly J, Buss EC, et al. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer. 2007; 109:1543–1549.